This is a multi-centre, randomised, double-blind, active-controlled, parallel-group
comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg
+hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+
amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the
double-blind period in essential hypertensive patients who fail to respond adequately to
telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a
6-week open-label run-in period taking T80/A5 mg.